TL;DR
For each dimension where one drug clearly wins, we name the winner. When the answer is "depends on your situation," the verdict text below the table explains why.
| Dimension | What the data says | Winner |
|---|---|---|
| Trial weight loss | Zepbound (20.9%) > Wegovy (14.9%) | Zepbound |
| Mechanism | Dual GLP-1/GIP (Zepbound) vs GLP-1 only (Wegovy) | Zepbound |
| Cash price at maintenance dose | LillyDirect $299-$449 vs NovoCare $299 maintenance dose | Tied |
| DTC starting dose | NovoCare $149 pill or $199 injection (intro through 6/30/26) vs LillyDirect $299 | Wegovy |
| Insurance coverage in 2026 | Both covered by most commercial; Wegovy has slight edge on Medicare Part D | Wegovy |
| Real-world track record | Wegovy launched 2021; Zepbound launched late 2023 | Wegovy |
| OSA indication | Zepbound is FDA-approved for obstructive sleep apnea | Zepbound |
Verdict
If you're optimizing for the highest expected weight loss and you can access Zepbound through insurance or LillyDirect at a price you can sustain, Zepbound is the trial-data winner. If you want the cheaper cash-pay path, the longer real-world safety record or the better odds on Medicare coverage, Wegovy is still the right call. Both are excellent drugs by the standards of pre-2021 weight loss medication.
Trial efficacy compared
The headline numbers are not from the same study, so direct comparison is approximate. The SURMOUNT-5 trial directly compared tirzepatide to semaglutide at obesity doses and found tirzepatide produced greater weight loss (20.2% vs 13.7% mean over 72 weeks), validating the cross-trial signal.
| Wegovy | Zepbound | |
|---|---|---|
| Registration trial | STEP-1 (NEJM, 2021) | SURMOUNT-1 (NEJM, 2022) |
| Duration | 68 weeks | 72 weeks |
| Mean weight loss (max dose) | 14.9% | 20.9% |
| Effect vs comparator | 12.4 pp vs placebo | 17.8 pp vs placebo |
| Patients losing ≥5% | 86.4% | 91% |
| Patients losing ≥15% | 50.5% | 56.7% |
2026 cash-pay cost compared
Both have a direct cash channel (NovoCare for Wegovy, LillyDirect for Zepbound) that is dramatically cheaper than the retail pharmacy cash price. Telehealth programs add a membership fee on top of medication cost.
| Channel | Wegovy | Zepbound |
|---|---|---|
| Retail cash | $1,349/mo | $1,099/mo |
| Manufacturer DTC | $149/mo pill (starter dose) or $199/mo injection intro (through 6/30/26 then $349) / $299 maintenance via NovoCare | $299-$449/mo via LillyDirect (vials) |
| With insurance + PA | $25-$50/mo with prior authorization | $25-$50/mo with prior authorization |
| Compounded | $175-$199/mo via 503A pharmacies | $175-$199/mo via 503A pharmacies (regulatory exposure; Strut $99 is an oral lozenge) |
When to choose Wegovy
Choose Wegovy if: (1) you're paying cash and starting out (NovoCare's $199 starter dose is hundreds cheaper than LillyDirect equivalents); (2) you're on Medicare Part D where Wegovy has broader formulary placement; (3) you want the drug with the longest real-world safety record at obesity-treatment doses; (4) your insurance has Wegovy on a lower formulary tier than Zepbound.
When to choose Zepbound
Choose Zepbound if: (1) you've tried semaglutide and didn't reach your goal weight (the dual-agonist mechanism produces greater average loss); (2) you have obstructive sleep apnea (the only GLP-1 with an FDA OSA indication as of 2024); (3) your insurance covers both equally; (4) you're cash-pay at the maintenance dose where LillyDirect's $299-$449/mo is close to NovoCare's $299 maintenance-dose price and the efficacy difference is the deciding factor.
Programs that prescribe each
Some visit links earn us a commission.
Top Wegovy programs
Top Zepbound programs
FAQ
Is Zepbound stronger than Wegovy?
Can you switch from Wegovy to Zepbound?
Are the side effects different?
Which is cheaper without insurance?
Are these covered by insurance?
Can a telehealth program prescribe both?
Read the full drug profiles
Editorial disclosure
GLP Chart is an editorial comparison site. We do not dispense, prescribe or fulfill medications. Trial data is from the cited NEJM publications. Pricing reflects publicly verified rates as of June 22. Talk to a licensed clinician about which medication is appropriate for you.
